Skip to main content

Evaluation of 18F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga-DOTATATE PET/CT



To evaluate the diagnostic efficacy of 18F-AlF-NOTA-octreotide (18F-OC) PET/CT compared with that of 68Ga-DOTATATE PET/CT.

Materials and methods

Twenty patients (mean age: 52.65 years, range: 24–70 years) with biopsy-proven neuroendocrine neoplasms (NENs) were enrolled in this prospective study. We compared the biodistribution profiles in normal organs based on the maximum standard uptake value (SUVmax) and mean standard uptake value (SUVmean), and uptake in NEN lesions by measuring the SUVmax on 18F-OC and 68Ga-DOTATATE PET/CT images. The tumor-to-liver ratio (TLR) and tumor-to-spleen ratio were calculated by dividing the SUVmax of different tumor lesions by the SUVmean of the liver and spleen, respectively. The Wilcoxon signed-rank test was used to compare nonparametric data. Data were expressed as the median (interquartile range).


In most organs, there were no significant differences in the biodistribution of 68Ga-DOTATATE and 18F-OC. 18F-OC had significantly lower uptake in the salivary glands and liver than 68Ga-DOTATATE. 18F-OC detected more lesions than 68Ga-DOTATATE. The uptake of 18F-OC in the tumors was higher in most patients, but the difference was not statistically significant relative to that of 68Ga-DOTATATE. However, the TLRs of 18F-OC were higher in most patients, including for lesions in the liver (p = 0.02) and lymph nodes (p = 0.02).


Relative to 68Ga-DOTATATE, 18F-OC possesses favorable characteristics with similar image quality and satisfactory NEN lesion detection rates, especially in the liver due to its low background uptake. 18F-OC therefore offers a promising clinical alternative for 68Ga-DOTATATE.


Neuroendocrine neoplasms (NENs) are a relatively rare and highly heterogeneous tumor derived from neuroendocrine cells. The incidence and prevalence of NENs have increased steadily over the past 40 years, with increasing awareness and emergence of better diagnostic tools [1]. This has been accompanied by a concomitant increase in the rate of NEN distant metastases, which negatively affects NEN treatment and survival [2]. Thus, effective NEN monitoring using sensitive imaging approaches is needed to detect progression and adapt treatment strategies.

NENs commonly express somatostatin receptors (SSTRs), making them amenable to molecular imaging with radionuclide-coupled somatostatin analogs as a diagnostic tool [3]. Currently, 68Ga-labeled somatostatin analogs (SSAs) for positron emission tomography/computed tomography (PET/CT) have been used in routine clinical practice [4, 5]. Relative to single-photon emission computed tomography (SPECT), PET has a higher spatial resolution, shorter imaging times, lower radiation exposure, and better lesion detection [6, 7]. Thus, PET scanning using 68Ga-labeled SSAs is critical for tumor detection rate, staging and restaging and post-therapy follow-up [4]. However, the use of 68Ga-labeled PET is limited by the high cost of 68Ge/68Ga generators [8] and the relatively short half-life of 68Ga (68 min). 18F-labeled (18F half-life: 106.9 min) SSAs have high tumor-to-background ratio (TBR) for NEN lesions; thus, these probes may be used as an alternative in NEN imaging and also allow for longer transport times [9, 10].

In recent years, there has been increased research on 18F-labeled agents [10,11,12]. 18F-AlF-NOTA-octreotide (18F-OC) exhibits satisfactory biodistribution and dosimetry profiles with a high NEN lesion detection rate [13]. A comparison of the imaging parameters of 18F-OC and 68Ga-DOTATATE for NENs in a small number of patients found that 18F-OC has excellent dynamics and imaging characteristics [14]. Here, we assessed the clinical applicability and efficacy of 18F-OC relative to those of 68Ga-DOTATATE in a larger group of patients.


Patients and study design

The research was approved by the institutional ethics review committee of Xiangya Hospital, Central South University for research purposes only (No. 20181001). All study participants gave written informed consent before the start of the study. Patients with clinically confirmed NENs were prospectively recruited into the study. Participants received an intravenous injection of 18F-OC and 68Ga-DOTATATE for PET/CT within 8 days (range: 1–8 days), except patients No. 1 (interval time: approximately 147 days without any treatment) and No. 15 (interval time: approximately 279 days without peptide receptor-radionuclide therapy (PRRT)).

68 Ga-DOTATATE and 18 F-OC preparation

68Ga-DOTATATE was synthesized using the acetone method on a fully automated Modular Lab system (Eckert & Ziegler, Germany), and quality control was performed as previously described [15]. The radiochemical purity of 68Ga-DOTATATE was > 90%. 18F-OC was produced as previously described [16] and under good manufacturing practice guidelines.

PET/CT image acquisition

The study was carried out with a General Electric PET/CT scanner (Discovery 690 Elite, General Electric Health care, Waukesha, Wis). 18F-OC PET/CT imaging was performed 60 min after the radiotracer was intravenously (IV) injected at a dose of 3.7–4.44 MBq (0.1–0.12 mCi) per kilogram of body weight. 68Ga-DOTATATE imaging was performed 50 min after an injection with a total activity of 194.4 ± 37.9 MBq. First, a low-dose CT scan (120 kV; automatic mAs; pitch, 1:1; slice thickness, 3.75 mm; matrix, 512 × 512) was performed from the head to mid-thigh for anatomical localization and attenuation correction. Next, PET scanning was performed, with 2 min per bed position. Finally, images were reconstructed using the 3-dimensional ordered-subsets expectation maximization algorithm with 2 iterations and 23 subsets.

Image analysis

Regions of interest (ROIs) were drawn on fused PET/CT images on a dedicated nuclear medicine AW 4.6 workstation (General Electric Healthcare) to obtain standardized uptake values (SUVs). 18F-OC and 68Ga-DOTATATE images were independently assessed by 2 experienced nuclear medicine physicians who were blinded to the patients and their medical information. The ROIs for measuring the maximum standard uptake value (SUVmax) and mean standard uptake value (SUVmean) in normal organs and tissues and the ROIs for measuring the SUVmax of NEN lesions were drawn on serial images. The mean SUVmax and SUVmean in the reference organs were evaluated by placing 3 consecutive ROIs (including the area with the highest uptake and that on the upper and lower slices based on visual assessment) inside the organ of interest, including pituitary, cerebral cortex, adrenal gland, uncinate process of the pancreas (PU), pancreas (except the PU), stomach, spleen, thyroid, salivary glands, liver, bone, renal parenchyma, small intestine, uterus (female), prostate (male), colon, lung, fat, myocardium, muscle, bladder wall, and blood pool, on both scans. Candidate lesions with activities greater than the physiologic uptake in the involved organs were considered lesions. These lesions were divided into 5 regions or groups: primary tumor, liver metastases, bone metastases, lymph node metastases, and metastases in other organs (lung, muscle, stomach, rectum, peritoneum, soft tissue, and thyroid). For patients with multiple lesions, at most 5 lesions with the highest uptake per organ were included in the uptake analysis. The tumor-to-liver ratio (TLR) and tumor-to-spleen ratio (TSR) were calculated by dividing the SUVmax of different tumor lesions by the SUVmean of the liver and spleen in each patients, respectively. All ratios on corresponding 18F-OC and 68Ga-DOTATATE scans were computed from the same layer on the 2 scans. All discrepant lesions between the images of the 2 radiotracers were identified by other imaging or patient follow-up (computed tomography (CT), magnetic resonance imaging (MRI), and PET/CT) and then classified as true- or false-positive findings.

Statistical analysis

Data analysis was performed using GraphPad Prism 6 (Version 6.01, 2012). Data are expressed as the median (interquartile range). Nonparametric data were compared using the Wilcoxon signed-rank test. P < 0.05 indicates statistical significance.


Twenty patients were prospectively enrolled in the study, and their clinical characteristics are summarized in Table 1. No patients received PRRT treatment between 68Ga-DOTATATE and 18F-OC PET/CT scans. Both radiotracers were tolerated well by all patients, and no adverse events were reported. The physiological uptake of 68Ga-DOTATATE and 18F-OC is shown in Fig. 1. 68Ga-DOTATATE and 18F-OC PET/CT scans were compared at the lesion and region levels and based on SUV.

Table 1 Patient clinical characteristics
Fig. 1

Uptake of 68Ga-DOTATATE and 18F-OC in normal organs was calculated in patients based on the mean SUVmax (a) and SUVmean (b). Significant differences between 68Ga-DOTATATE and 18F-OC are indicated. **: p =  < 0.01, *: p =  < 0.05

Biodistribution of 68 Ga-DOTATATE and 18 F-OC

Similar to that of 68Ga-DOTATATE, the highest SUVmax values for 18F-OC were recorded in the spleen, adrenal gland, renal parenchyma, pituitary gland, liver, and PU. Lower SUVmax and SUVmean values were observed in the salivary glands, myocardium, bone, lung muscle, fat, and cerebral cortex. In most organs, the biodistribution of 68Ga-DOTATATE was not significantly different from that of 18F-OC. Relative to 68Ga-DOTATATE, 18F-OC had significantly lower uptake in organs such as the salivary glands, liver, pancreas, bone, renal parenchyma, and prostate (Fig. 1).

Comparison of tumor detection rates between 68 Ga-DOTATATE and 18 F-OC PET/CT

This study included 20 NEN patients. Examinations using 68Ga-DOTATATE and 18F-OC PET/CT revealed that 19 patients had lesions and 1 patient had no lesions. Follow-up examination confirmed lesions in the 19 patients and that patient No. 1 had no lesions. Table 2 shows the discordant lesions examined by 68Ga-DOTATATE and 18F-OC PET/CT.

Table 2 Patients with discordant lesions on 18F-OC and 68Ga-DOTATATE PET/CT

In the region-based comparison, 9 patients had primary tumors on both 18F-OC and 68Ga-DOTATATE images. In addition, there were 4 patients staged with unknown primary lesions. Sixteen patients had metastases on 68Ga-DOTATATE PET/CT, and 17 patients had metastases on 18F-OC PET/CT. 18F-OC demonstrated a higher ability to detect liver lesions (Fig. 2). In 11 patients with liver metastases, 100% (11/11) and 90.9% (10/11) of patients showed liver metastases on 18F-OC and 68Ga-DOTATATE scans, respectively. 18F-OC also detected peritoneal lesions more effectively than 68Ga-DOTATATE in 1 patient (No. 9).

In the lesion-based examination, 68Ga-DOTATATE and 18F-OC PET/CT detected 152 and 177 focal lesions, respectively (p = 0.54). A total of 149 tumor lesions (9 in the primary sites, 93 in the liver, 20 in the lymph node, 8 in the bone, and 19 in other sites) were concordantly detected on both 18F-OC and 68Ga-DOTATATE PET/CT scans. An additional 30 lesions were detected by one of the scans only (Table 2). Both 18F-OC and 68Ga-DOTATATE had lesions that could not be detected by another imaging agent (Fig. 3). 18F-OC detected 28 lesions (23 in the liver, 2 in the lymph node, and 3 in the peritoneum) not visualized with 68Ga-DOTATATE. 68Ga-DOTATATE identified 1 lymph node lesion and 1 retroperitoneal lesion not seen with 18F-OC. 18F-OC detected significantly more liver lesions (116 vs. 93, p < 0.01). There was a difference of 10 liver metastases detected by the 2 radiotracers in patient No. 14 (Fig. 2), which were confirmed as true lesions by follow-up CT and MR. Additionally, 18F-OC detected 3 peritoneal lesions in patient No. 9. Regarding lymph node lesions, both 18F-OC and 68Ga-DOTATATE detected 1 lesion that was not clearly detected by the other imaging agent. In addition, 18F-OC and 68Ga-DOTATATE PET/CT had comparable effectiveness in detecting primary tumors and bone metastases.

Fig. 2

More liver lesions were detected by 18F-OC (d–f) than by 68Ga-DOTATATE (ac). Maximum intensity projection image (a, f) shows more liver metastases present in a 50-year-old patient with a grade II primary pancreatic neuroendocrine tumor. Although transaxial fused PET/CT (b, d) and PET images (c, e) acquired with 68Ga-DOTATATE and 18F-OC show an equal number of liver lesions in this slice, the lower background level of 18F-OC uptake by normal liver (df) better delineates liver lesions by making the lesions appear to have more obvious uptake and sharper edges relative to background levels of 68Ga-DOTATATE uptake (ac)

Fig. 3

Both 18F-OC and 68Ga-DOTATATE had lesions that could not be detected by another imaging agent. PET/CT images acquired with 68Ga-DOTATATE and 18F-OC for patient No. 19 (a, b) and No. 20 (c, d). The 18F-OC fusion image (b) found an increased uptake in a retroperitoneal lymph node, while the uptake of this lymph node was not significantly increased on 68Ga-DOTATATE (a) image. However, in another patient, the 18F-OC fusion image (d) shows that the uptake in one retroperitoneal lesion was not obvious, while the uptake of 68Ga-DOTATAE was significant (c)

Fig. 4

Bar chart representing the maximum standardized uptake value (SUVmax, a), tumor-to-liver ratio (TLR, b) and tumor-to-spleen ratio (TSR, c) of 18F-OC. TLR (b) and TSR (c) were calculated by dividing the SUVmax of tumor lesions by the patient-specific SUVmean of the liver and spleen, respectively. The TLRs for lesions in the liver and lymph nodes were significantly higher with 18F-OC (p = 0.02 and p = 0.02, respectively). All other SUVmax, TLR and TLR calculations did not show significant differences

Lesion uptake analysis found that 18F-OC uptake was slightly higher than 68Ga-DOTATATE uptake in primary tumors and metastases, but there were no significant differences (primary tumor: 25.01 (16.52–38.58) versus 19.08 (16.37–34.28), p = 0.80; metastases: 18.24 (11.25–37.48) versus 17.13 (8.99–28.72), p = 0.33). However, some lesions had higher 18F-OC uptake and others lesions had higher 68Ga-DOTATATE uptake, even among lesions of the same patient. For example, on PET/CT for suspected retroperitoneal pheochromocytoma in patient No. 20, 3 lesions were seen in the neck region, with higher 68Ga-DOTATATE uptake than 18F-OC uptake in 2 of the neck lesions (SUVmax 56.59 vs. 53.11 and 27.19 vs. 15.13), but higher 18F-OC uptake in the other lesion (SUVmax 115.14 vs. 111.45) (Additional file 1: Fig. S1). Furthermore, in liver and lymph node lesions, the 18F-OC TLR was higher than that with 68Ga-DOTATATE (p = 0.02, Fig. 4). However, the 18F-OC TSR was not significantly higher than that of 68Ga-DOTATATE for primary tumor or metastases (Fig. 4).

In our study, we found that despite physiological uptake in the PU (mentioned above), three cases of nodules with abnormal density or signal in the PU on CT or MRI showed abnormal uptake in the PU on 68Ga-DOTATATE and 18F-OC PET (Additional file 2: Fig. S2). The SUVmax were as follows: 41.1, 86.7, 16.4, respectively in 68Ga-DOTATATE and 27.5, 94.3, 15.3, respectively in 18F-OC.


Here, we prospectively assessed the performance of 18F-OC PET/CT relative to 68Ga-DOTATATE PET/CT in 20 NEN patients. The 18F-OC had a favorable biodistribution profile and was not inferior to 68Ga-DOTATATE in tumor uptake, TLR and TSR.

Our data showed that the 18F-OC distribution in organs was similar to that of 68Ga-DOTATATE. 18F-OC accumulation was very high in the spleen, which was similar to that of 68Ga-labeled DOTA-SSAs. Because both radiotracers were mainly excreted by the urinary system, higher uptake was seen in the kidneys. However, the overall uptake of 18F-OC in organs was lower than that of 68Ga-DOTATATE, especially in the liver, where the background 68Ga-DOTATATE uptake was 1.5 times greater than that of 18F-OC. We found that the salivary glands showed visible differences between the 2 radiotracers, which was consistent with past findings that 68Ga-DOTATATE uptake by salivary glands was four–sixfold higher than that of 18F-OC, mainly because of different radiotracer clearance times [14].

Because of high physiological uptake due to high SSTR2 expression in the PU and artifacts caused by respiratory movement, focal pancreatic lesions and lesions around the head of the pancreas may be obscured. Here, we found that both 18F-OC and 68Ga-DOTATATE had high uptake nodules in the PU, and other imaging examinations (CT or MRI) showed changes in the shape, signal or density of these nodules (Additional file 2: Fig. S2). Other imaging agents based on 68Ga-labeled radionuclides also demonstrated high sensitivity and specificity for detecting lesions (93.6% and 90%, respectively) in the PU [17]. We considered that results of a previous study [17] and ours could indicate SSA- PET, combined with morphological information (CT or MRI), especially if performed with enhanced CT or MRI, will improve the accuracy of lesions in the PU. But our number of cases was relatively small (n = 3). Thus, larger studies are needed to confirm these findings.

18F-OC and 68Ga-DOTATATE were highly sensitive in detecting lesions, and there were no differences in their overall diagnostic efficacy. Relative to 68Ga-DOTATATE, 18F-OC can detect lesions better (177 vs. 152), especially lesions in the liver (116 vs. 93), probably due to the lower background level of 18F-OC uptake in the liver. This finding is of great clinical significance, as it may affect treatment methods. For example, in patient No. 3, liver lesions were detected with 18F-OC but not 68Ga-DOTATATE. In patient No. 10, only one lesion was detected in the left lobe with 68Ga-DOTATATE, while 18F-OC detected another lesion in the right lobe of the liver, which was confirmed to be NEN metastases through pathology. These data are consistent with findings by Pauwels et al. [14] that 18F-OC detects more liver lesions.

Our data did not uncover differences between 68Ga-DOTATATE and 18F-OC in the detection of bone lesions (8 vs. 8). However, Pauwels et al. [14] found that 18F-OC detects more bone lesions. The differences between the 2 studies may be due to the small number of bone lesions in our study. Regarding lymph node lesions, both imaging radiotracers detected unique lesions. Additionally, 18F-OC detected 3 relatively small peritoneal metastases (diameter: < 5 mm) in patient No. 9, which were missed by 68Ga-DOTATATE. This is attributable to 18F being a typical short-distance positron emitter with better spatial resolution [18], which may be better suited for detecting small lesions. Thus, the capacity of 18F-OC to detect lesions is similar to that of 68Ga-DOTATATE, and 18F-OC may detect liver lesions more efficiently.

In this study, the SUVmax of 18F-OC was higher than that of 68Ga-DOTATATE, but the difference was not statistically significant. Interestingly, relative to 68Ga-DOTATATE, 18F-OC had a better target-to-background ratio. In this study, using liver and spleen for background comparisons, we found the 18F-OC TLRs for lesions in the liver and lymph node were significantly higher than those of 68Ga-DOTATATE, probably due to low liver background with 18F-OC. However, this finding differs from the results from Pauwels et al. [14] that the 18F-OC SUVmax for all lesions were significantly lower than those of 68Ga-DOTATATE, but there was no difference in TBR, which may be attributable to the small sample size. We also found that some patients exhibited higher 68Ga-DOTATATE uptake in lesions while others had higher 18F-OC uptake, and even within the same patient, some lesions had higher 68Ga-DOTATATE uptake while others had greater 18F-OC uptake; this is probably because of NEN heterogeneity [19]. The reason for the difference between the two radiotracers still needs further study.

Taken together, we found that 18F-OC had similar characteristics to 68Ga-DOTATATE in terms of physiological distribution, lesion detection, and lesion uptake. However, 18F-OC was relatively better in detecting liver lesions than 68Ga-DOTATATE. The two radiotracers had significantly difference TLRs, which is an important parameter for lesion detection.


The most significant limitation of this study was the lack of pathological confirmation of most lesions, which was not performed due to the ethical implications of pathologically examining all patient lesions. Thus, all lesions found with 18F-OC and 68Ga-DOTATATE were confirmed using alternative imaging approaches such as 18F-FDG PET, CT, or MRI. In addition, due to the small size of the study group and the small number of patients with higher-grade NENs, we could not evaluate the correlation between uptake and tumor grade. Future studies will involve a larger sample size.


Overall, 18F-OC shows a favorable biodistribution, in which the uptake in various organs is similar to or even lower than that of 68Ga-DOTATATE. 18F-OC can detect liver lesions better than 68Ga-DOTATATE, with a better tumor-to-liver ratio. However, both 18F-OC and 68Ga-DOTATATE have similar detection rates for lesions in other organs. In general, 18F-OC has great potential as an alternative to 68Ga-DOTATATE in the absence of a 68Ge/68Ga generator. In the future, more patients are needed for comparisons between 68Ga-DOTATATE and 18F-OC to verify the value of 18F-OC in clinical applications.


  1. 1.

    Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.

    Article  Google Scholar 

  2. 2.

    Sackstein PE, O’Neil DS, Neugut AI, Chabot J, Fojo T. Epidemiologic trends in neuroendocrine tumors: an examination of incidence rates and survival of specific patient subgroups over the past 20 years. Semin Oncol. 2018;45:249–58.

    Article  Google Scholar 

  3. 3.

    Johnbeck CB, Knigge U, Kjær A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol (London, England). 2014;10:2259–77.

    CAS  Article  Google Scholar 

  4. 4.

    Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms withGa-DOTA-conjugated somatostatin receptor targeting peptides and F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588–601.

    CAS  Article  Google Scholar 

  5. 5.

    Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med Off Publ Soc Nucl Med. 2018;59:66–74.

    CAS  Google Scholar 

  6. 6.

    Sadowski SM, Neychev V, Millo C, et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for DetectingGastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34:588–96.

    CAS  Article  Google Scholar 

  7. 7.

    Schreiter NF, Brenner W, Nogami M, et al. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:72–82.

    Article  Google Scholar 

  8. 8.

    Banerjee SR, Pomper MG. Clinical applications ofGallium-68. Appl Radiat Isot Incl Data Instrum Methods Use Agric Ind Med. 2013;76:2–13.

    CAS  Google Scholar 

  9. 9.

    Coenen HH, Elsinga PH, Iwata R, et al. Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences. Nucl Med Biol. 2010;37:727–40.

    CAS  Article  Google Scholar 

  10. 10.

    Ilhan H, Lindner S, Todica A, et al. Biodistribution and first clinical results of F-SiFAlin-TATE PET: a novel F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;47:870–80.

    Article  Google Scholar 

  11. 11.

    Berends AMA, Kerstens MN, Bolt JW, et al. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (F-FDOPA-PET) performed for imaging of neuroendocrine tumors. Eur J Endocrinol. 2018;179:125–33.

    CAS  Article  Google Scholar 

  12. 12.

    Narayan A, Yan Y, Lisok A, et al. A side-by-side evaluation of [F]FDOPA enantiomers for non-invasive detection of neuroendocrine tumors by positron emission tomography. Oncotarget. 2019;10:5731–44.

    Article  Google Scholar 

  13. 13.

    Long T, Yang N, Zhou M, et al. Clinical application of 18F-AlF-NOTA-octreotide PET/CT in combination with 18F-FDG PET/CT for imaging neuroendocrine neoplasms. Clin Nucl Med. 2019;44:452–8.

    Article  Google Scholar 

  14. 14.

    Pauwels E, Cleeren F, Tshibangu T, et al. [(18)F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [(68)Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020;47:3033–46.

    Article  Google Scholar 

  15. 15.

    Zhernosekov KP, Filosofov DV, Baum RP, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med Off Publ Soc Nucl Med. 2007;48:1741–8.

    CAS  Google Scholar 

  16. 16.

    Laverman P, McBride WJ, Sharkey RM, et al. A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med. 2010;51:454–61.

    CAS  Article  Google Scholar 

  17. 17.

    Kroiss A, Putzer D, Decristoforo C, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:514–23.

    CAS  Article  Google Scholar 

  18. 18.

    Conti M, Eriksson L. Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys. 2016;3:8.

    Article  Google Scholar 

  19. 19.

    Maschauer S, Heilmann M, Wangler C, Schirrmacher R, Prante O. Radiosynthesis and preclinical evaluation of (18)F-fluoroglycosylated octreotate for somatostatin receptor imaging. Bioconjug Chem. 2016;27:2707–14.

    CAS  Article  Google Scholar 

Download references


Not applicable.


This study has received funding from the National Natural Science Foundation of China (No. 91859207 and No. 81771873).

Author information




JH, TL, ZH, MZ, NY, DC, SZ, and SH contributed to the study design and coordination of the study. JH, TL, and DC contributed to management of registration of cases, collected PET-data. MZ and NY contributed to tracer synthesis. JH, TL, MZ, NY, DC, and SH contributed to image quality control, analysis, and data interpretation. JH, TL, and ZH contributed to statistical analysis. JH, TL, and SZ were involved in collection of clinical data. JH, TL, and SH contributed to drafting and revising the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Shuo Hu.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

. Inconsistent uptake of 68Ga-DOTATATE (a–c) and 18F-OC in different lesions of a patient.

Additional file 2.

. The lesions of 68Ga-DOTATATE (a–c) and F-OC in the uncinate process of the pancreas (PU) of two patients.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hou, J., Long, T., He, Z. et al. Evaluation of 18F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga-DOTATATE PET/CT. EJNMMI Res 11, 55 (2021).

Download citation